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ABSTRACT 
Background & Aims: Screening for Barrett’s esophagus (BE) with conventional 
esophagogastroduodenoscopy (C-EGD) is expensive. We assessed the performance of a 
clinic-based, single use transnasal capsule endoscope (EG Scan II) for the detection of BE, 
compared to C-EGD as the reference standard. 
Methods: We performed a prospective multicenter cohort study of patients with and without 
BE recruited from 3 referral centers (1 in the United States and 2 in the United Kingdom). Of 
200 consenting participants, 178 (89%) completed both procedures (11% failed EG Scan 
due to the inability to intubate the nasopharynx). The mean age of participants was 57.9 
years and 67% were male. The prevalence of BE was 53%. All subjects underwent the 2 
procedures on the same day, performed by blinded endoscopists. Patients completed 
preference and validated tolerability (10-point visual analogue scale [VAS]) questionnaires 
within 14 days of the procedures.    
Results: A higher proportion of patients preferred the EG Scan (54.2%) vs the C-EGD 
(16.7%) (P<.001) and the EG Scan had a higher VAS score (7.2) vs the C-EGD (6.4) 
(P=.0004). No serious adverse events occurred. The EG Scan identified any length BE with 
a sensitivity value of 0.90 (95% CI, 0.83–0.96) and a specificity value of 0.91 (95% CI, 0.82–
0.96). The EG Scan identified long segment BE with a sensitivity value of 0.95 and short 
segment BE with a sensitivity values of 0.87. 
Conclusion: In a prospective study, we found the EG Scan to be safe and to detect BE with 
higher than 90% sensitivity and specificity. A higher proportion of patients preferred the EG 
Scan to C-EGD. This device might be used as a clinic-based tool to screen populations at 
risk for BE. ISRCTN registry identifier: 70595405; ClinicalTrials.gov no: NCT02066233. 
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INTRODUCTION 
Recent society guidelines have provided more support to screening individuals with multiple 
risk factors for Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC), such as 
chronic reflux symptoms, central obesity and a family history of EAC or BE 1, 2, though the 
number of risk factors which may trigger a decision to screen and, more importantly, the 
tools to screen remain unclear. 
While conventional esophagogastroduodenoscopy (C-EGD) remains the reference standard 
test to diagnose BE, it is not suitable for wide spread screening due to direct and indirect 
costs associated with sedation, recovery and monitoring3. The technical success rate of 
unsedated transnasal endoscopy (TNE) is comparable to C-EGD and the former was more 
preferred by patients4. However, the conventional TNE devices still require dedicated 
endoscopy suites with specialized equipment and decontamination facilities, hence, they 
have limited potential for widespread use in population screening 5. Recent reports have 
demonstrated the acceptability, safety and accuracy of modified endoscopic transnasal 
techniques (EndoSheath®) 6, 7 in screening for BE. The EndoSheath® transnasal 
esophagoscope is portable and utilizes a disposable sheath with a biopsy channel that 
covers the endoscope to reduce the risk of cross contamination, but it still requires cleaning 
of the scope with alcohol wipe and an enzymatic detergent after every use.   
The EG Scan ™ II (second generation) transnasal video esophagoscope (Intromedic Ltd., 
Seoul, South Korea) incorporates a disposable probe which omits the need for reprocessing. 
Moreover, it is highly compact and portable therefore can be used in the clinic or any other 
setting with rapid turnaround of patients.  The aim of the current study was to assess the 
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technical feasibility, quality, safety, acceptability and accuracy of clinic-based TNE using the 
EG Scan compared to C-EGD as the reference standard.  
MATERIALS AND METHODS 
Study design and settings  
This was a prospective diagnostic cohort study performed in three tertiary referral centers, 2 
in the UK (Nottingham and Cambridge University Hospitals) and 1 in the USA (Mayo Clinic, 
Rochester, MN). All procedures were performed between July 2012 and October 2015 and 
all participants provided written informed consent. The trial received approval from the East 
Midlands research ethics committee (UK) and from the Mayo Clinic (Rochester, USA) 
Institutional Review Boards. It was prospectively registered (ISRCTN registry identifier: 
70595405; ClinicalTrials.gov identifier: NCT02066233). The research was conducted and 
reported according to the standards for the reporting of diagnostic accuracy studies 
(STARD) statement 8. All authors had access to the study data and reviewed and approved 
the final manuscript. 
Participants 
Consecutive adult patients referred for clinical C-EGD with and without histologically 
confirmed BE of any length were invited to participate. BE patients were undergoing clinically 
indicated endoscopy for surveillance or therapy of BE related neoplasia. Patients without 
known BE were undergoing endoscopy for other clinical indications which included 
dyspepsia, heartburn, dysphagia and nausea/vomiting. Exclusion criteria were recurrent 
epistaxis (more than once a week); complete nasal obstruction; diseases of the nasal cavity; 
and anticoagulant use. All eligible patients were identified from the endoscopy referral 
database and approached by the study coordinators either via a letter or phone call to inform 
them of study details. Subjects were asked to express their interest in taking part or not 
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either at the time of the phone call or by returning a pre-paid self-addressed reply envelope 
to the study coordinators.     
Interventions 
All patients underwent TNE first using the EG Scan (index test) followed by C-EGD 
(reference standard) on the same day by two different operators who were blinded to the 
findings of each other. TNE procedures were performed by certified endoscopists (S.S.S. in 
Nottingham; M.D.P. in Cambridge; P.G.I. and M.H. at Mayo Clinic) who had limited prior 
experience in using the EG Scan device (performed 1-3 procedures in the past), but had 
performed over 1000 C-EGD procedures. P.G.I also had experience in performing TNE 
(n=200).   
At both procedures, a note was made of any suspected BE and the segment length was 
defined using the Prague criteria 9. Demographic and procedure data were collected and 
patients were asked to fill in validated questionnaires within 14 days after the procedures.  
The EG Scan™ II system 
The second generation EG Scan system (Figure 1) components are described in 
supplementary Table 1.  
Endoscopy procedures 
The EG Scan procedure was performed in an outpatient clinic room with the patient sitting in 
a chair next to the physician’s desk. Prior to commencing the procedure, participants were 
given a 100-ml liquid oral drink which is a mixture of water; orange cordial flavoring; a 
mucolytic (10 mls of 200 mg/ml N-acetylcysteine); and an anti-foaming agent (1ml of 
Simeticone 40 mg/ml) in order to improve visualization of the mucosa (UK centers only). A 
topical aerosol spray (Lidocaine Hydrochloride 5% and Phenylephrine Hydrochloride 0.5%) 
was applied to the patient’s nares (3-4 sprays) 3-5 minutes prior to the procedure. The probe 
was introduced into the right or left nares and advanced into the proximal esophagus under 
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direct vision. The operator inspected the esophagus and the gastro-esophageal junction 
(indicated by the top of the proximal gastric folds) both in forward and retro-flexion views. 
Following the procedure, the probe was disconnected from the hand-held controller and 
discarded. The system was dismantled and stored in the accompanying suitcase (figure 1A).  
The C-EGD procedures were performed in the endoscopy suite using a 9.8-mm diameter 
high definition endoscope (GIF-260H, Olympus Keymed, Essex, UK or GIF-H180, Olympus 
America, Center Valley, PA). Patients in the UK centers were offered either a topical 
anesthetic spray (applied to the posterior pharynx, 5-10 sprays, Lidocaine 10mg/dose, 
Xylocaine, AstraZeneca, Luton, UK) or conscious sedation (intravenous midazolam with or 
without pethidine or fentanyl) for their C-EGD procedures, while all the USA participants 
received conscious sedation.      
Patient questionnaires 
All post-procedure questionnaires were administered by the study coordinators and 
completed by patients with the endoscopists blinded. Patients’ tolerability was measured 
using a validated 10-point visual analogue scale (VAS) 10. Patients were asked to describe 
their overall experience of both procedures by placing a cross on a line from “0” (worst ever 
experience) to “10” (best ever experience). Patients were asked which procedure they would 
prefer to have in the future if clinically indicated (EG Scan, or C-EGD, or either)). Tolerability 
and preference questionnaires were completed using prepaid self-addressed return 
envelopes at least 24 hours after procedures to allow for the complete resolution of sedation 
effects. We also measured the degree of gagging, choking, discomfort, and nasal pain 
immediately after EG Scan using the same scale where “0” is none and “10” is severe. 
Patients were also asked to complete a validated short form Spielberger State Trait Anxiety 
Inventory (STAI-6) questionnaire 11 at baseline and after both EG Scan and C-EGD 
procedures. STAI-6 scores were calculated as per the developers’ guidelines, with clinically 
significant anxiety considered to be a score of ≥4011. 
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Outcome measures 
Study outcome measures included:   
1. The technical feasibility and quality of the endoscopic examinations measured as: (i) rate 
of successful intubation (the ability to traverse the upper esophageal sphincter and 
visualize the esophageal mucosa); (ii) rate of complete visualization of the tubular 
esophagus, squamocolumnar junction, and gastroesophageal junction; and (iii) duration 
of EG Scan examination (time from intubation to extubation). 
2. Safety of procedures measured as the rate of serious adverse events or need for 
hospitalization assessed immediately and within 14 days (telephone call from the study 
coordinator) after procedures.  
3. Patients’ acceptability of both procedures measured using validated questionnaires as 
detailed above. 
4. The accuracy of EG Scan (index test) in detecting: (i) any length BE; (ii) long segment BE 
(LSBE) defined as circumferential (C) or maximal (M) length ≥3 cm by Prague criteria9; 
and (iii) short segment BE (SSBE) defined as C or M <3 cm using C-EGD as the 
reference standard.  
Statistical analysis 
Data on the diagnostic accuracy and acceptability of this novel screening tool compared to 
C-EGD were not available to reliably inform sample size calculations. We assessed a group 
of 200 patients with the aim to include approximately 50% with known BE (prevalence). 
Based upon clinical experience, we expected the EG Scan sensitivity to be 0.85 to 0.90. In 
this scenario, a sample size of 141 to 200 patients will give us a margin of error of +/-0.07, 
which will be clinically meaningful to evaluate this device as a diagnostic test for BE12. We 
used paired t-test (normally distributed differences) and Wilcoxon signed rank test (non-
normally distributed differences) to compare measurements of continuous variables. The 
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Chi-squared or Fisher exact tests were used to compare categorical variables. Statistical 
computations were performed using the Stata version 12.0 software (Stata Corporation, 
College Station, Texas, USA).  
RESULTS 
Baseline characteristics 
Two hundred patients were enrolled (Nottingham n=50; Cambridge n=50; Mayo Clinic 
n=100). The mean (+/- standard deviation (SD)) age was 58 years (+/-14) and BE 
prevalence was 53%. The median (interquartile range (IQR)) length of BE was C0 (IQR 0-2) 
and M2 (IQR 1-4). Baseline characteristics of all participants are outlined in table 1.     
Technical feasibility, quality and safety 
178 out of 200 patients (89%) completed both procedures and included in the analysis. 
Twenty two patients 11%) failed EG Scan due to the inability to intubate the nasopharynx. 
Those were equally split between the UK (n=11; 5.5%) and the USA (n=11; 5.5%) centers. 
(Figure 2). The rate of complete visualization was similar between the two techniques (Table 
2). The mean duration of the EG Scan examination was 4.0 (+/- 4.0) minutes. 120 out of 178 
(67%) C-EGD procedures were performed under sedation. Of those, 110 received 
intravenous midazolam (median dose 5 mg; IQR 3-6) with or without intravenous pethidine 
(n=35; median dose 50 mg; IQR 0-62.5) or intravenous fentanyl (n=70; median dose 100 
mcg; IQR 75-100). Ten patients received propofol sedation.   
There were 5 cases of non-serious adverse events which included: (i)  probe technical 
failure (n=2) towards the end of procedures where the up/down lever at the handle failed to 
achieve tip deflection and the procedure was terminated; (ii) two patients (1.1%) experienced  
vasovagal symptoms after abdominal distension secondary to air insufflation during the 
procedure. This self-terminated after a short period of observation; and (iii) one patient 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
(0.55%) developed self-limiting epistaxis. All those 5 patients were included in the analysis. 
No serious adverse events occurred. 
Acceptability 
The overall tolerability (VAS scores) was better with EG Scan compared to C-EGD (Table 2). 
When stratified by sedation and center location, the VAS scores were comparable between 
the EG scan and C-EGD in the subgroup of patients that either received sedation or where 
from the USA center. There was a significant reduction in the mean (+/- standard error of the 
mean (SEM)) anxiety scores post EG Scan (30.5 +/-0.8; p=0.0003) and post C-EGD (28.7 
+/-0.9; p<0.0001) compared to baseline (33.4 +/-0.8).  
Accuracy  
Ninety four out of the 178 patients (53%) had BE (n=40 LSBE; n=54 SSBE). Data on 
accuracy are shown in table 3. The EG Scan missed 9 cases of BE, 2 of those were LSBE 
(Figure 2). In both of those, the squamo-columnar junction was poorly visualized with white 
light imaging on C-EGD and had to be confirmed with narrow band imaging. Example 
findings of EG Scan are shown in Figure 3.  
DISCUSSION 
Principal findings 
Results from this multicenter study evaluating the clinical feasibility of using the EG Scan 
device as a clinic-based screening test for BE demonstrate that the procedure is safe, well 
tolerated, and accurate, when compared to C-EGD. Significantly more patients preferred the 
EG Scan over C-EGD independent of sedation use for the latter.  
The difference in technical success rate for EG Scan compared to C-EGD in this study was -
11% (89% vs. 100%, respectively). This is larger than expected compared to values reported 
in the literature4. All operators had a comparably limited experience of using the EG Scan at 
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baseline, therefore, a learning curve which may impact on both the technical and diagnostic 
performance of this technique might be present. We have previously demonstrated that 
studies using TNE <5.9 mm insertion diameter reported significantly higher success rates 
compared to those using ≥5.9 mm4. The insertion diameter of the EG Scan was 6.1 mm 
which is relatively large compared to other modern TNE devices 5. A third generation EG 
Scan prototype with a smaller insertion diameter of 5.0 mm has been developed. This may 
allow for further improvements in device performance compared to the current prototype.  
Results on accuracy of EG Scan for the detection of BE in this study were comparable to 
those reported for other conventional TNE devices (non-portable and non-disposable)13, 14. 
Shariff et al 13, reported a sensitivity and specificity of 0.98 and 0.99, respectively, for TNE 
using a FUJINON endoscope (EG530N, FUJIFILM Europe GmbH, Düsseldorf, Germany) 
with a 5.9 mm insertion diameter. However, they only included patients with a minimum 
circumferential length BE of 2 cm and all procedures were performed in a dedicated 
endoscopy suite. Our data suggest that undertaking TNE in a clinic room using a 
significantly more compact device (EG Scan) can still achieve high sensitivity in this 
subgroup of patients with longer segment BE.  
One limitation of the EG Scan compared to other TNE devices and C-EGD is the lack of a 
working channel, hence it is not possible to obtain biopsy samples from endoscopically 
suspected areas of BE. Nevertheless, it must be emphasized that we evaluated this device 
as a potential tool for future use in a two-step BE screening program in the primary care 
setting. If such a program is implemented using this technology, then the issue of biopsy 
acquisition becomes less critical, because all cases with suspected BE will require a clinical 
C-EGD for surveillance biopsies and risk stratification as per current practice. The cost of the 
EG Scan probe compared to other tools needs to be taken into account, however, this can 
vary significantly depending on supply and demand. Moreover, there are several other 
important issues to consider when comparing the EG Scan to other screening tools, such as 
turnover time, screening uptake, accuracy, acceptability, yield for other pathologies, and 
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impact on quality of life. These factors must be incorporated into a cost-effectiveness 
modelling study to evaluate different screening approaches.  
A capsule sponge (CytospongeTM) coupled with a biomarker (TFF3) has been evaluated in a 
case-control and in a primary care setting. In the case-control study (1100 patients (647 
cases and 463 controls)15, the success rate of the capsule sponge was 94% and the overall 
sensitivity and specificity for BE ≥C1 or ≥M3 were 0.80 (95%CI 0.76-0.83) and 0.92 (95%CI 
0.90-0.95), respectively. In the primary care setting with a prevalence of 3%, the sensitivity 
and specificity of the test for the detection of BE ≥C1 were 0.73 and 0.94, respectively16. 
Screening using a non-endoscopic device was also found to be cost-effective in a separate 
economic modelling study17. The procedure can be performed by less skilled operators with 
potential for widespread applicability. The sampling has advantages for the evaluation of 
cellular and molecular features suggestive of inflammation, infection, intestinal metaplasia 
and dysplasia18, 19, however on the other hand it will not provide real time visualization of the 
BE segment as well as other high risk features associated with it, such as erosive 
esophagitis, ulcers, strictures, and polypoid lesions (Figure 3). All these trade-offs need to be 
carefully weighed when comparing different screening technologies.     
Screening tests should be acceptable to patients with minimal psychological impact in order 
to improve the uptake and cost-effectiveness of the screening program 20. Data from this 
study demonstrate a positive impact of EG Scan on patients’ satisfaction with a significant 
reduction in anxiety scores after procedures. TNE screening for BE can be performed 
successfully by physician extenders after a short training program 21. This may reduce 
operator costs and increase access to future screening programs. TNE screening was also 
found to be more cost effective than C-EGD screening with lower direct and indirect costs3, 
22
.  
Study strengths and limitations 
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This multi-center study had several strengths and limitations. The trial conduct and reporting 
conforms to current guidelines for undertaking diagnostic accuracy studies which is an 
important strength8, 23. We used validated VAS 10 and 3-item (EG Scan or C-EGD or either) 
questionnaires to measure tolerability and preference, respectively. Those were self-
administered at home with the endoscopist blinded to eliminate interviewer bias 24. The 
response rate was 94% (168 out of 178) for both VAS and preference questionnaires (Table 
2), hence response bias remains unlikely. Moreover, patients were offered the choice of 
“either” for their procedure preference to minimize forced choice bias, where respondents 
who have no preference will be forced to select an answer (EG Scan or C-EGD) that may or 
may not reflect their true feelings 24. We cannot rule out social desirability or obsequiousness 
bias where respondents may alter their questionnaire responses in the direction they 
perceive to be desired by the investigator 24, however, this limitation pertains to the majority 
of questionnaire study designs. Patients were not offered monetary compensation nor any 
other incentive (such as an earlier appointment) to participate in the study.  
This was a non-randomized cohort study and no pilot data were available to adequately 
inform sample size calculations. The order of procedures and operators should be 
randomized in future trials in order to eliminate bias in preference estimates towards one 
procedure or the other. Due to the performance of this study in tertiary centers using a case-
control design, the prevalence of BE in this study was high compared to the general 
population6, 16. The diagnostic accuracy can be overestimated if the test is evaluated in 
patients already known to have the disease , rather than in a relevant screening population 
25
. The proportion of false positive diagnoses will be higher and false negative ones will be 
lower when the current sensitivity and specificity is applied to lower prevalence populations 
(Supplementary box 1). However, for this initial study since the prevalence of BE is low26, we 
opted to enrich the study population with patients known to have BE in order to obtain 
estimates of sensitivity and specificity.     
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We did not evaluate interobserver agreement. The EG Scan was less sensitive in detecting 
SSBE compared to LSBE. This could be due to a limitation of the EG Scan imaging quality 
or could equally be a result of poor agreement between the EG Scan and C-EGD operators 
on the presence or absence of SSBE. Seven out of the 9 cases missed by the EG Scan had 
a circumferential length of 0 cm and maximal length of 1-2 cm (Figure 2). The interobserver 
agreement on presence of circumferential BE <1 cm is known to be poor (0.22) compared to 
BE ≥1 cm (0.72)9.  
Conclusions 
Clinic-based TNE using the EG Scan was feasible, safe, and highly acceptable by patients 
compared to C-EGD. The overall technical success rate of EG Scan was lower than 
expected compared to literature estimates for the TNE technique. This could be due to 
factors such as operator expertise and the insertion diameter of the EG Scan probe. EG 
Scan accuracy for the detection of BE was high. Future studies should evaluate the utility of 
this technique in the intended screening population. In particular, important outcomes such 
as participation rates, learning curve, yield of screening, and cost-effectiveness need to be 
assessed.  
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TABLES 
Table 1: Baseline characteristics of the study cohort (n=200). Data presented as number 
(%) or mean (+/- standard deviation) as applicable. 
Variable 
No Barrett’s 
(n=95) 
Barrett’s 
(n=105) 
Total 
(n=200) 
Age 52.7 (+/-14.6) 62.5 (+/-11.7) 57.9 (+/-14.0) 
Male sex 53 (55.8%) 81 (77.1%) 134 (67.0%) 
White ethnicity 89 (93.7%) 104 (99.0%) 193 (96.5%) 
Body mass index 28.4 (+/-5.6) 29.6 (+/-5.2) 29.0 (+/-5.4) 
Education 
   
Primary 9 (9.6%) 20 (19.2%) 29 (14.7%) 
Secondary 31 (33.0%) 39 (37.5%) 70 (35.4%) 
College 26 (27.7%) 25 (24.0%) 51 (25.8%) 
University 28 (29.8%) 20 (19.2%) 48 (24.2%) 
Smoking 9 (9.5%) 10 (9.5%) 19 (9.5%) 
NSAIDs use 18 (19.0%) 17 (16.2%) 35 (17.5%) 
Proton pump inhibitors 
use 51 (53.7%) 99 (94.3%) 150 (75.0%) 
H2-receptors blockers 
use 12 (12.6%) 12 (11.4%) 24 (12.0%) 
Aspirin use 19 (20.0%) 31 (29.5%) 50 (25.0%) 
Family history EAC 6 (6.3%) 10 (9.6%) 16 (8.0%) 
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NSAIDs, Non-steroidal anti-inflammatory drugs; EAC, esophageal adenocarcinoma. 
 
Table 2: Technical feasibility, quality and acceptability of endoscopic assessments (n=200). 
Data presented as number (%), mean (+/- standard deviation), or median (interquartile range 
(IQR)). 
Variable EG Scan C-EGD P value 
Rate of successful intubation 178 (89%) 200 (100%) <0.001 
Rate of complete visualization† 175 (98.3%) 177 (99.4%) 0.3146 
Discomfort scales (0= none 10= worst) 
   
Gagging/retching 2 (IQR 0-3) -  
Choking 0 (IQR 0-1) -  
Discomfort 2 (IQR 1-3) -  
Nasal pain (EG only) 1 (IQR 0-3) -  
VAS score total (n=168)‡ 7.2 (+/-2.0) 6.4 (+/-2.7) 0.0004 
sedation subgroup (n=113) 7.1 (+/-2.0) 7.3 (+/-2.2) 0.4543 
no sedation subgroup (n=55) 7.4 (+/-1.9) 4.4 (+/-2.0) <0.001 
UK centers subgroup (n=81) 7.3 (+/-2.0) 5.1 (+/-2.8) <0.001 
USA center subgroup (n=87)¶ 7.2 (+/-2.0) 7.6 (+/-2.0) 0.1556 
Preference total (n=168)§ 91 (54.2%) 28 (16.7%) <0.001 
sedation subgroup (n=113) 50 (44.3%) 23 (20.4%) <0.001 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
no sedation subgroup (n=55) 41 (74.5%) 5 (9.1%) 0.001 
UK centers subgroup (n=81) 52 (64.2%) 13 (16.1%) <0.001 
USA center subgroup (n=87)¶ 39 (44.8%) 15 (17.2%) <0.001 
C-EGD, conventional esophagogastroduodenoscopy; VAS, visual analogue scale; † 
calculated for patients who were successfully intubated and underwent both procedures 
(n=178). Visualization was incomplete in 3 patients (EG Scan) due to secretions and one 
patient (C-EGD) due to intolerance with constant gagging despite sedation; ‡ 168/178 
returned the tolerability (VAS) and preference questionnaires; § 119/168 expressed 
preference for either EG Scan or C-EGD while the remaining 49/168 had no preference 
(either); ¶ all patients in this subgroup received sedation for C-EGD. 
Table 3: Accuracy of the EG Scan for Barrett’s esophagus (BE) diagnosis. Data presented 
as decimal fraction (95% confidence interval) 
 Sensitivity Specificity AUROC 
Any length BE 0.90 (0.83 – 0.96) 0.91 (0.82 – 0.96) 0.91 (0.86 – 0.95) 
Long segment BE 0.95 (0.83 – 0.99) 1.0 (0.96 – 1.0) 0.98 (0.94 – 1.0) 
Short segment BE 0.87 (0.75 – 0.95) 0.91 (0.82 – 0.96) 0.89 (0.83 – 0.94) 
AUROC, area under the receiver operating characteristic curve 
FIGURE LEGENDS 
Figure 1: The EG Scan™ II system. (A) the portable case with four main parts; (B) the 
image processor (top left), disposable probe (top right), air tube (bottom right) and hand-held 
controller (bottom left); (C) the system connected and ready for use; (D) close view of the 
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capsule probe tip. (Reproduced with permission from Sami SS, et al. Copyright John Wiley 
and Sons). 
Figure 2: Study flowchart. BE, Barrett’s esophagus; †8 cases false positive on EG Scan, 7 
were classed as C0M1 and 1 classed as C0M2 by Prague classification; ‡EG Scan missed 9 
cases of BE, those were classed as C5M6 (n=1), C9M9 (n=1), C0M2 (n=4), C0M1 (n=3) by 
Prague classification. 
Figure 3: Image quality and example findings of EG Scan. (A) Normal; (B, C) Barrett’s 
esophagus; (D) Schatzki’s ring; (E) Erosive esophagitis; (F) Esophageal adenocarcinoma.  
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Significance of this study 
Background 
• Screening for Barrett’s esophagus (BE) with conventional esophagogastroduodenoscopy 
(C-EGD) is not cost effective. 
• Unsedated transnasal endoscopy (TNE) is safe, accurate and acceptable alternative to 
C-EGD. 
• Existing TNE devices have limited applicability for widespread use in the community 
setting due to limited portability and the need for decontamination. 
Findings 
• Clinic-based TNE using the EG Scan device was safe, feasible and acceptable. 
• A higher proportion of patients preferred the EG Scan over C-EGD regardless of the use 
of sedation for the latter.  
• The EG Scan was accurate for the detection of BE of any length with superior accuracy 
for long segment compared to short segment BE.  
Implications for patient care 
• This device could potentially serve as a tool for screening populations at risk for BE.  
• Future studies should evaluate the utility of this technique in the intended screening 
population. In particular, important aspects such as participation rates, operator training, 
and yield of screening need to be explored. 
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Supplementary table 1: The EG Scan™ II system components.  
1. A disposable probe (diameter 3.4 mm, length 1088 mm) which is made from 
human compliance plastic and sealed with a biocompatible adhesive. The probe is 
designed for single use; therefore the risk of cross infection is eliminated. It 
contains: 
a) Capsule at the tip (diameter 6.1 mm) which produces images at a speed of 30 
frames per second with a 125° field of view and 3-5 0 mm view depth. The 
camera capsule comprises four white light- emitting diodes (LEDs) and a 
complementary metal-oxide semiconductor (CMOS) image sensor with 
400×400 pixel array. 
b) Bending wire to facilitate tip deflection with bending angle of 160° up/160° 
down. 
c) Data connector to transmit captured images from tip of the capsule to the 
processor. 
d) Air insufflation channel. There is no suction or biopsy capability. 
2. A hand-held controller which has freeze, capture and air insufflation buttons with 
an up/down lever at the handle to facilitate tip deflection. The probe is attached to 
the controller. 
3. An image processor which incorporates a free air displacement system (5L/min). 
Images are transmitted from the tip of the probe to the processor and then 
displayed on a laptop computer screen via USB connection. The E.G. view™ 
computer software is used to visualize videos and images.   
4. An air tube which connects the processor to the probe in order to facilitate air 
insufflation during the procedure. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Supplementary box 1: Impact of disease prevalence on positive and negative 
predictive values of the test (based on current sensitivity and specificity). 
A- Example calculation: at a study prevalence of 0.53 for Barrett’s esophagus (BE) = 0.53 
with “disease” and 0.47 with “no disease”, therefore proportion of patients with true 
positive (TP) result = sensitivity (0.90) * prevalence (0.53) = 0.48 and the remaining 0.05 
are false negative (FN). Similarly, proportion of true negative (TN) = specificity (0.91) * 1-
prevalence (0.47) = 0.43 and the remaining 0.04 are false positive (FP).  
Therefore: positive predictive value (PPV) = TP/TP+FP = 0.48/0.48+0.04 = 0.92 
                  Negative predictive value (NPV) = TN/TN+FN = 0.43/0.43+0.05 = 0.90 
 
B- Example calculation: at a lower prevalence of 0.08 for BE = 0.08 with “disease” and 
0.92 with “no disease”, therefore proportion of patients with TP result = sensitivity (0.90) * 
prevalence (0.08) = 0.072 and the remaining 0.008 are FN. Similarly, proportion of TN = 
specificity (0.91) * 1-prevalence (0.92) = 0.84 and the remaining 0.08 are FP.  
Therefore: positive predictive value (PPV) = TP/TP+FP = 0.072/0.072+0.08 = 0.47 
                  Negative predictive value (NPV) = TN/TN+FN = 0.84/0.84+0.008 = 0.99 
 
 
